Robert Alan Schueren Sells 4,256 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRAGet Rating) COO Robert Alan Schueren sold 4,256 shares of the business’s stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $41.56, for a total transaction of $176,879.36. Following the transaction, the chief operating officer now owns 4,226 shares in the company, valued at approximately $175,632.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Robert Alan Schueren also recently made the following trade(s):

  • On Monday, January 9th, Robert Alan Schueren sold 2,244 shares of Natera stock. The stock was sold at an average price of $37.62, for a total transaction of $84,419.28.
  • On Tuesday, January 3rd, Robert Alan Schueren sold 4,856 shares of Natera stock. The stock was sold at an average price of $39.55, for a total transaction of $192,054.80.
  • On Wednesday, December 28th, Robert Alan Schueren sold 1,382 shares of Natera stock. The stock was sold at an average price of $39.84, for a total transaction of $55,058.88.

Natera Price Performance

Shares of NTRA stock opened at $42.94 on Wednesday. Natera, Inc. has a 1 year low of $26.10 and a 1 year high of $74.82. The firm’s 50 day moving average is $39.55 and its 200-day moving average is $44.06. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of -7.56 and a beta of 1.28. The company has a current ratio of 3.10, a quick ratio of 2.95 and a debt-to-equity ratio of 0.78.

Natera (NASDAQ:NTRAGet Rating) last announced its earnings results on Tuesday, November 8th. The medical research company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.17. Natera had a negative net margin of 70.34% and a negative return on equity of 109.07%. The company had revenue of $210.64 million for the quarter, compared to analyst estimates of $208.31 million. Sell-side analysts forecast that Natera, Inc. will post -5.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Large investors have recently modified their holdings of the stock. Ronald Blue Trust Inc. acquired a new position in shares of Natera during the second quarter worth approximately $26,000. Parallel Advisors LLC lifted its holdings in Natera by 84.2% in the second quarter. Parallel Advisors LLC now owns 829 shares of the medical research company’s stock valued at $29,000 after buying an additional 379 shares during the period. Assetmark Inc. lifted its holdings in Natera by 93.6% in the second quarter. Assetmark Inc. now owns 873 shares of the medical research company’s stock valued at $31,000 after buying an additional 422 shares during the period. Quadrant Capital Group LLC lifted its holdings in Natera by 4,595.2% in the second quarter. Quadrant Capital Group LLC now owns 986 shares of the medical research company’s stock valued at $35,000 after buying an additional 965 shares during the period. Finally, First Horizon Advisors Inc. lifted its holdings in Natera by 970.2% in the third quarter. First Horizon Advisors Inc. now owns 1,006 shares of the medical research company’s stock valued at $44,000 after buying an additional 912 shares during the period. 93.81% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on NTRA. Robert W. Baird lowered their target price on shares of Natera from $72.00 to $65.00 in a research note on Wednesday, November 9th. BTIG Research lowered their target price on shares of Natera from $95.00 to $75.00 in a research note on Wednesday, November 9th. Piper Sandler reissued an “overweight” rating and issued a $70.00 target price on shares of Natera in a research note on Tuesday, January 17th. StockNews.com began coverage on shares of Natera in a research note on Wednesday, October 12th. They issued a “sell” rating on the stock. Finally, Stephens lowered their target price on shares of Natera to $67.00 in a research note on Wednesday, November 16th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $80.00.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.